Press Releases

BOSTON and SYDNEY — 16 November 2018 — GI Dynamics®, Inc. (ASX:GID), a medical device company that is developing EndoBarrier® is pleased to announce that,  following stockholder approval obtained on 30 October 2018 at the Company’s Special Meeting, it has successfully completed the issue of the...

BOSTON and SYDNEY — 1 November 2018 — GI Dynamics, Inc. (ASX:GID), a medical device company that is developing EndoBarrier, held a Special Meeting on Monday, 29 October 2018 at 5:00pm United States Eastern Daylight Time (being Tuesday, 30 October 2018 at 8:00am Australian Eastern Daylight Time)...

BOSTON and SYDNEY — 16 October 2018 — GI Dynamics, Inc. (ASX:GID), a medical device company that is developing EndoBarrier for patients with type 2 diabetes and obesity, is pleased to confirm, further to its announcement released on 21 September 2018, the attached proxy statement and notice of a...

BOSTON and SYDNEY — 5 October 2018 — GI Dynamics, Inc. (ASX:GID), a medical device company that is developing EndoBarrier for patients with type 2 diabetes and obesity, is pleased to announce the selection of Intertek as the company’s notified body to continue working toward attaining the...

BOSTON and SYDNEY — 21 September 2018 — GI Dynamics, Inc. (ASX:GID), a medical device company that is developing EndoBarrier for patients diagnosed with type 2 diabetes and obesity, is pleased to confirm, further to its announcement on 20 September 2018, that it has closed Tranche 1 of the...

BOSTON and SYDNEY — 20 September 2018— GI Dynamics, Inc. (ASX:GID), a medical device company that is developing EndoBarrier for patients diagnosed with type 2 diabetes and obesity, is pleased to announce it has received binding commitments for a private placement of 347,222,250 CHESS Depositary...

BOSTON and SYDNEY – 15 August 2018 – GI Dynamics Inc. (ASX: GID), a medical device company that is developing EndoBarrier for patients diagnosed with type 2 diabetes and obesity, announces it will update shareholders on 2018 second quarter results as reported on Form 10Q for the three and...

Pivotal trial to focus on reduction of hemoglobin A1c for patients diagnosed with type 2 diabetes and obesity • Primary Endpoint        Reduction of HbA1c at 1 year • Planned Study Size                                           Stage I: 50 EndoBarrier / 17 control                                  ...

BOSTON and SYDNEY — 9 July 2018 — GI Dynamics® Inc. (ASX: GID), a medical device company that is developing EndoBarrier® for patients diagnosed with type 2 diabetes and obesity, is pleased to announce the first report from the Association of British Clinical Diabetologists (ABCD) Worldwide...

BOSTON and SYDNEY — 4 July 2018 — GI Dynamics® Inc. (ASX: GID), a medical device company that is developing EndoBarrier® for patients with type 2 diabetes and obesity, is pleased to announce further positive results from the ongoing National Health Service (NHS) EndoBarrier Service in the U.K.,...